This site is intended for UK healthcare professionals only and contains promotional information.UK Flag Please visit the MHRA Yellowcard site to report an Adverse Event.

Clinical use of antibiotics for difficult to treat pathogens in patients with cystic fibrosis

Prescribing Information for QUOFENIX®(delafloxacin), VABOREM®(meropenem/vaborbactam) and TENKASI® (oritavancin) can be found below under Useful Resources

Clinical use of antibiotics for difficult to treat pathogens in patients with cystic fibrosis

Presented by: Professor John E Moore, CF Consultant Microbiologist, Northern Ireland Regional Adult Cystic Fibrosis Centre, Belfast City Hospital.
Content Summary: 1. Understand the microbiology in treating complicated chest infections in CF patients.
2. Update on treatment options for MDR gram-negatives in respiratory.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to A. Menarini Farmaceutica Internazionale SRL. Phone 0800 085 8678 or email: [email protected]


These medicinal products are subject to additional monitoring.

Professor John Moore

Professor John Moore

Professor John E. Moore is Clinical Microbiologist at Belfast City Hospital, incorporating the Northern Ireland Public Health Laboratory, where he has worked since 1993. Belfast City Hospital is a university teaching hospital of Queen’s University of Belfast Medical School, as well as the Regional Centre in Northern Ireland for adults with cystic fibrosis. He is Honorary Professor in the School of Medicine, Dentistry and Biomedical Sciences, Queen’s University, Belfast, as well as Honorary Professor in the School of Biomedical Sciences, Ulster University, and past External Examiner for Clinical Microbiology at Trinity College, Dublin. His clinical and research interests include the microbiology of cystic fibrosis, on which he has published approximately 100 peer-reviewed publications, as well as antimicrobial resistance.

PP-AI-UK-0483 April 2024

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store.

Adverse events should also be reported to A. Menarini Farmaceutica Internazionale SRL.

Phone 0800 085 8678